Summary of all included studies | ||
---|---|---|
n/N | Association | |
Mortality | 4/4 (100%) | Favorable (++) |
Cardiometabolic risk factors | ||
WC | 8/12 (67%) | Favorable (++) |
Obese/ adiposity/ BMI | 4/10 (40%) | Inconsistent (??) |
Fat mass/ percent body fat | 3/3 (100%) | Favorable (+) |
SBP | 1/6 (17%) | No association (00) |
DBP | 0/4 (0%) | No association (00) |
High BP | 1/5 (20%) | No association (00) |
HDL-C | 4/11(36%) | Inconsistent (??) |
LDL -C | 0/3 (0%) | No association (0) |
Triglycerides | 8/11 (73%) | Favorable (++) |
Dyslipidemia | 0/1 (0%) | No association (0) |
Glucose | 2/11 (18%) | No association (00) |
Glycated hemoglobin | 0/2 (0%) | No association (0) |
Insulin/ diabetes | 5/6 (83%) | Favorable (++) |
HOMA β | 1/2 (50%) | Inconsistent (?) |
HOMA R | 3/6 (50%) | Inconsistent (?) |
CRP | 1/4 (25%) | No association (0) |
Metabolic syndrome | 5/7 (71%) | Favorable (++) |
Lipid accumulation | 1/2 (50%) | Inconsistent (?) |
Framingham risk score | 0/1 (0%) | No association (0) |
Mental health and cognitive function | ||
Mental health | 1/1 (100%) | Favorable (+) |
Well-being | 1/1 (100%) | Favorable (+) |
Cognitive health | 1/2 (50%) | Inconsistent (?) |
Other outcomes | ||
Medical multimorbidity | 2/2 (100%) | Favorable (+) |
Prostate-specific antigen | 1/1 (100%) | Favorable (+) |